548 filings
Page 7 of 28
8-K
9l5gud d6
25 Apr 18
Other Events
12:00am
8-K
jcqhvktacd
4 Apr 18
Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart Center Hamburg
12:00am
8-K
afesud6
2 Apr 18
Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
12:00am
8-K
publaop3 sy97tch7
8 Mar 18
Other Events
12:00am
8-K
mykqepn8jta7
14 Feb 18
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures
12:00am
8-K
37fh6jyzxa png44zy
14 Feb 18
Abiomed Receives Approval for Expanded FDA Indication for Cardiomyopathy with Cardiogenic Shock
12:00am
8-K
98y2b4a8dbal8l93
1 Feb 18
Abiomed Announces Q3 Fy 2018 Record Revenue of $154 Million, Up 34% Over Prior Year
12:00am
8-K
jdtykt8v
8 Jan 18
Abiomed Announces Preliminary Q3 Fy 2018 Revenue of $154 Million, Up 34% Over Prior Year
12:00am
8-K
knojg2z6y 1i7f
26 Oct 17
Results of Operations and Financial Condition
12:00am
8-K
enehrll6naxs
21 Sep 17
Abiomed Receives FDA PMA Approval for Impella RP® for Right Heart Failure
12:00am
8-K
318j8uua
12 Sep 17
Entry into a Material Definitive Agreement
12:00am
8-K
joe6kadt
28 Aug 17
Abiomed Announces Resignation of Chief Financial Officer and Welcomes Back Former
12:00am
8-K
ki9r5ppz ps
15 Aug 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
746telg ckejbhvs1
3 Aug 17
Other Events
12:00am
8-K
1tx flt0o4
27 Jul 17
Abiomed Announces Q1 Fy 2018 Revenue of $132.5 Million, Up 29% Over Prior Year
12:00am
DEFA14A
dogav
23 Jun 17
Additional proxy soliciting materials
12:00am